Randomised, double-blind factorial trial (n=24) testing three repeated microdoses of LSD (20 µg; three dosing days) versus placebo in healthy volunteers to assess effects on mood, sleep, neuroplasticity and related biomarkers.
Randomised, double-blind interventional study in healthy volunteers comparing three repeated morning versus evening microdoses of LSD (20 µg) against placebo in a factorial design; three dosing days are administered with interspersed non-dosing days.
Primary outcome is mood; secondary outcomes include measures of sleep, neuroplasticity (including BDNF and slow-wave sleep), cognitive performance, emotion regulation, markers of well-being, cortisol and endocannabinoid levels.
Three repeated microdoses of LSD (20 µg) given on dosing days; factorial design comparing morning vs evening dosing versus placebo.
Matched placebo on same schedule